Skip to main content

Table 4 Primary outcome results

From: Heterogeneity amongst GLP-1 RA cardiovascular outcome trials results: can definition of established cardiovascular disease be the missing link?

 

ELIXA [22]

LEADER [24]

SUSTAIN-6 [25]

EXSCEL [27, 28]

Harmony outcomes [30]

PIONEER 6 [32]

REWIND [34]

 

Lixisenatide

Placebo

Liraglutide

Placebo

Semaglutide

Placebo

Exenatide

Placebo

Albiglutide

Placebo

Semaglutide

Placebo

Dulaglutide

Placebo

N

3034

3034

4668

4672

1648

1649

7356

7396

4731

4732

1591

1592

4949

4952

MACE (per 100 patient-yr)

6.40

6.30

3.40*

3.90

3.24*

4.44

3.70

4.00

4.57*

5.87

2.90*

3.70

2.35*

2.66

CV death

2.30

2.40

1.20*

1.60

1.29

1.35

1.40

1.50

1.61

1.72

0.70

1.40

1.22

1.34

Non-fatal MI

4.20

4.10

1.60

1.80

1.40

1.92

(2.10)

(fatal or nonfatal)

(2.10)

(fatal or nonfatal)

(2.43) *

(fatal or nonfatal)

(3.26)

(fatal or nonfatal)

1.80

1.50

0.80

0.84

Non-fatal stroke

1.00

0.90

0.90

1.00

0.80*

1.31

(0.80)

(fatal or nonfatal)

(0.90)

(fatal or nonfatal)

(1.25)

(fatal or nonfatal)

(1.45)

(fatal or nonfatal)

0.60

0.80

0.52*

0.69

UA

0.20

0.10

(0.7)

(0.7)

(0.65)

(0.80)

N/A

N/A

N/A

N/A

(0.50)

(0.30)

(0.34)

(0.30)

  1. CV cardiovascular, MACE major adverse cardiovascular outcome, MI myocardial infarction, N/A not applicable, UA unstable angina
  2. *Statistically significant difference